SGX Pharmaceuticals Reports Toxicity With Lead Oncology Candidate In Phase I
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Grey acknowledges setback but points to second MET inhibitor and Novartis-partnered BCR-ABL inhibitor program as promising.